Morte Súbita na Doença de Parkinson: Qual o envolvimento do coração?
DOI:
https://doi.org/10.34024/rnc.2021.v29.12642Palavras-chave:
Doença de Parkinson, morte súbita, SUDPAR, anormalidades cardíacas, disfunções autonômicasResumo
Introdução. A Doença de Parkinson (DP) é a segunda doença neurodegenerativa mais comum, trata-se de uma desordem neurológica progressiva, podendo atingir mais de 1% da população acima de 60 anos, na maioria homens. A taxa de mortalidade de pacientes com DP é maior quando comparada com a população em geral. As causas dessa mortalidade elevada são desconhecidas, mas os fatores de risco cardiovascular podem desempenhar um papel importante. Nesse contexto, a morte súbita na doença de Parkinson (SUDPAR), corresponde a um evento importante que, embora raro, também ocorre. Objetivo. O objetivo dessa revisão é apresentar os principais achados na literatura quanto à relação entre anormalidades cardiovasculares e disfunções autonômicas com a morte súbita na DP. Método. Realizou-se pesquisas nas bases de dados Scielo, Google scholar e PubMed pelo termo Parkinson’s disease em combinação com os termos (i) sudden death, (ii) sudden unexpected death, (iii) SUDPAR, (iv) cardiac abnormalities e (v) autonomic disfunctions. Todas as publicações relevantes foram consideradas. Resultados. Existem ainda poucos estudos na literatura sobre SUDPAR, sendo que, de 2006 a 2020, foram publicados 22 trabalhos entre cartas ao editor, artigos originais, revisões e relatos de caso. Pesquisas clínicas e experimentais sugerem que anormalidades cardíacas e disfunções autonômicas desempenham um papel fundamental. Conclusão. Diversos estudos apresentam o envolvimento cardíaco na DP, sendo que disfunções autonômicas são causas frequentes de morte em pacientes com essa doença. A colaboração entre médicos e pesquisadores é fundamental para identificar abordagens que, considerando a investigação cardiológica, ofereçam a possibilidade de prevenção da SUDPAR.
Downloads
Métricas
Referências
Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson’s disease. Rev Neurologiq 2016;172:14–26. https://doi.org/10.1016/j.neurol.2015.09.012
Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Trans 2017;124:901-5. https://doi.org/10.1007/s00702-017-1686-y
Schneider RB, Iourinets J, Richard IH. Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegen Dis Manag 2017;7:365-76. https://doi.org/10.2217/nmt-2017- 0028
Kieburtz K, Wunderle KB. Parkinson’s disease: Evidence for environmental risk factors. Mov Dis 2013;28:8-13. https://doi.org/10.1002/mds.25150
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 2016;15:1257–72. https://doi.org/10.1016/S1474-4422(16)30230-7
Hayes MT. Parkinson’s Disease and Parkinsonism. Am J Med 2019;132:802-7. https://doi.org/10.1016/j.amjmed.2019.03.001
Scorza FA, do Carmo AC, Fiorini AC, Nejm MB, Scorza CA, Finsterer J, et al. Sudden unexpected death in Parkinson’s disease (SUDPAR): a review of publications since the decade of the brain. Clinics 2017;72:649-51. https://doi.org/10.6061/clinics/2017(11)01
D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G, et al. Long-term survival of Parkinson’s disease: A population-based study. J Neurol 2006;253:33-7. https://doi.org/10.1007/s00415-005-0916-7
Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study. Neurology 2008;70:1423-30. https://doi.org/10.1212/01.wnl.0000310414.85144.ee
Xu J, Gong DD, Man CF, Fan Y. Parkinson’s disease and risk of mortality: Meta-analysis and systematic review. Acta Neurol Scan 2014;129:71-9. https://doi.org/10.1111/ane.12201
Pinter B, Diem-Zangerl A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, et al. Mortality in Parkinson’s disease: A 38-year follow-up study. Mov Dis 2015;30:266-9. https://doi.org/10.1002/mds.26060
Scorza FA, Cavalheiro EA, Scorza CA, Ferraz HB. Sudden unexpected death in Parkinson’s disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilep Behav 2016;57:124-5. https://doi.org/10.1016/j.yebeh.2016.01.035
Matsumoto H, Sengoku R, Saito Y, Kakuta Y, Murayama S, Imafuku I. Sudden death in Parkinson’s disease: A retrospective autopsy study. J Neurol Sci 2014;343:149-52. https://doi.org/10.1016/j.jns.2014.05.060
Silva AS, Ariza D, Dias DPM, Crestani CC, Martins-Pinge MC. Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA. Life Sci 2015;127:82-9. https://doi.org/10.1016/j.lfs.2015.01.032
Scorza FA, Scorza CA, Ferraz Ii HB. Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way. Clinics 2016;71:59-61. https://doi.org/10.6061/clinics/2016(02)01
Renoux C, Dell’Aniello S, Khairy P, Marras C, Bugden S, Turin TC, et al. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson’s disease. Bri J Clin Pharmacol 2016;82:461-72. https://doi.org/10.1111/bcp.12964
Rajput AH, Rozdilsky B. Dysautonomia in Parkinsonism: A clinicopathological study. J Neurol Neurosur Psychiatr 1976;39:1092-100. https://doi.org/10.1136/jnnp.39.11.1092
Alonso A, Huang X, Mosley TH, Heiss G, Chen H. Heart rate variability and the risk of Parkinson disease: The Atherosclerosis Risk in Communities study. Ann Neurol 2015;77:877-83. https://doi.org/10.1002/ana.24393
Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J Clin Neurosci 2018;53:1–5. https://doi.org/10.1016/j.jocn.2018.04.031
Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson’s disease: Time to stage III, IV, V and to motor fluctuations. Mov Dis 2006;21:1384-95. https://doi.org/10.1002/mds.20993
Wang G, Li XJ, Hu YS, Cheng Q, Wang CF, Xiao Q, et al. Mortality from Parkinson’s disease in China: Findings from a five-year follow up study in Shanghai. Can J Neurol Sci 2015;42:242-7. https://doi.org/10.1017/cjn.2015.49
Scorza FA, Cavalheiro EA, Scorza CA, Ferraz HB. Sudden unexpected death in Parkinson’s disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilep Behav 2016;57:124-5. https://doi.org/10.1016/j.yebeh.2016.01.035
Nishida N, Yoshida K, Hata Y. Sudden unexpected death in early Parkinson’s disease: neurogenic or cardiac death? Cardiovascul Pathol 2017;30:19-22. https://doi.org/10.1016/j.carpath.2017.06.001
Scorza FA, Tufik S, Scorza CA, Andersen ML, Cavalheiro EA. Sudden unexpected death in Parkinson’s disease (SUDPAR): sleep apnea increases risk of heart attack. Sleep Breat 2017;21:965-6. https://doi.org/10.1007/s11325-017-1511-8
Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Sudden unexpected death in Parkinson’s disease (SUDPAR): A fatal event that James Parkinson did not address. Age Ageing 2018;47:627. https://doi.org/10.1093/ageing/afy064
Scorza FA, Fiorini AC, de Almeida ACG, Scorza CA, Finsterer J. In brief: Sudden unexpected death in Parkinson’s disease. Acta Neurol Scan 2018;138:264-5. https://doi.org/10.1111/ane.12971
Rodrigues LD, Oliveira LF, Shinoda L, Scorza CA, Faber J, Ferraz HB, et al. Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone. Sci Rep 2019;9. https://doi.org/10.1038/s41598-019-45518-z
Nejm MB, Andersen ML, Tufik S, Finsterer J, Scorza FA. Sudden death in Parkinson’s disease: Unjustifiably forgotten. Parkinsonis Relat Dis 2019;58:88-9. https://doi.org/10.1016/j.parkreldis.2018.08.012
Zhang Y, Wang G. Response to: Sudden death in Parkinson’s disease: Unjustifiably forgotten. Parkinsonis Relat Dis 2019;58:87. https://doi.org/10.1016/j.parkreldis.2018.08.013
Nejm MB, Andersen ML, Tufik S, Finsterer J, Scorza FA. Sudden unexpected death in Parkinson’s disease: why do neuroscientists still ignore this condition? Neurol Sci 2019;40:413-4. https://doi.org/10.1007/s10072-018-3581-1
Menezes-Rodrigues FS, Scorza CS, Fiorini AC, Caricati-Neto A, Scorza CA, Finsterer J, et al. Sudden unexpected death in Parkinson’s disease: why is drinking water important? Neurodegen Dis Manag 2019;9:241-6. https://doi.org/10.2217/nmt-2019-0010
Rodrigues LD, Oliveira LF, Scorza CA, Andersen ML, Tufik S, Finsterer J, et al. REM sleep without atonia as prodromal marker of Lewy body disease: Fake news or the real deal? Parkinsonis Relat Dis 2019;67:34-5. https://doi.org/10.1016/j.parkreldis.2019.09.017
Rodrigues LD, Oliveira LF, Scorza CA, Andersen ML, Tufik S, Finsterer J, et al. We never speak about sudden unexpected death in Parkinson’s disease. Eur J Neurol 2020;27:e30. https://doi.org/10.1111/ene.14217
Alves M, Caldeira D, Ferro JM, Ferreira JJ. Reply to the letter ‘We never speak about sudden unexpected death in Parkinson’s disease. Eur J Neurol 2020;27:e29. https://doi.org/10.1111/ene.14216
Scorza FA, de Almeida ACG, Scorza CA, Fiorini AC, Finsterer J. Pro-inflammatory Cytokines and Sudden Death in Parkinson’s Disease: a Missing Piece of the Jigsaw Puzzle. J Neuroim Pharmacol 2020;15:570-1. https://doi.org/10.1007/s11481-020- 09950-7
Rodrigues LD, Oliveira LF, Scorza CA, Scorza FA, Andersen ML, Tufik S, et al. Sudden unexpected death in Parkinson’s disease: Who would think of the thyroid gland? Parkinsonis Relat Dis 2020;81:54-5. https://doi.org/10.1016/j.parkreldis.2020.10.010
Scorza FA, de Almeida ACG, Cysneiros RM, Scorza CA, Finsterer J. Letter to the editor: sudden death in Parkinson ́s disease: treating hypertension in the elderly is essential. Exp Opin Pharmacother 2021:1-2. https://doi.org/10.1080/14656566.2021.1833611
Jost WH. Reply to: Sudden Death In Parkinson ́s Disease: Treating Hypertension In The Elderly. Exp Opin Pharmacother 2020. https://doi.org/10.1080/14656566.2021.1833606
Micheli F, Gatto E, Fernandez Pardal M, Paradiso G. Domperidone and Parkinson’s disease. Medicina 1988;48:218. https://doi.org/10.1007/978-3-642- 73899-9_20
Lertxundi U, Echaburu SD-, Soraluce A, Garcia M, Osante BR-, Aguirre C. Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard? Curr Drug Saf 2013;8:63-8. https://doi.org/10.2174/1574886311308010009
Bacchi S, Chim I, Kramer P, Postuma RB. Domperidone for Hypotension in Parkinson’s Disease: A Systematic Review. J Parkinsons Dis 2017;7:603-17. https://doi.org/10.3233/JPD-171209
Rossi M, Giorgi G. Domperidone and Long QT Syndrome. Curr Drug Saf 2010;5:257-62. https://doi.org/10.2174/157488610791698334
Heranval A, Lefaucheur R, Fetter D, Rouille A, le Goff F, Maltete D. Drugs with potential cardiac adverse effects: Retrospective study in a large cohort of parkinsonian patients. Rev Neurologiq 2016;172:318-23. https://doi.org/10.1016/j.neurol.2015.11.007
Deguchi K, Sasaki I, Tsukaguchi M, Kamoda M, Touge T, Takeuchi H, et al. Abnormalities of rate-corrected QT intervals in Parkinson’s disease - A comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 2002;199:31-7. https://doi.org/10.1016/S0022-510X(02)00079-5
Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Junghanns S, et al. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Trans 2008;115:1527-36. https://doi.org/10.1007/s00702-008-0127-3
Finsterer J, Wahbi K. CNS-disease affecting the heart: Brain-heart disorders. J Neurol Sci 2014;345:8-14. https://doi.org/10.1016/j.jns.2014.07.003
Oka H, Mochio S, Sato H, Katayama K. Prolongation of QTc interval in patients with parkinson’s disease. Eur Neurol 1997;37:186-9. https://doi.org/10.1159/000117432
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Luis F Sierra, Noemi S Araújo, Fúlvio A Scorza
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Publicado: 2021-08-20
Português
English
Español
